Edgewise Therapeutics (EWTX) Accumulated Depreciation (2020 - 2026)

Edgewise Therapeutics has reported Accumulated Depreciation for 7 years, with the latest figure at $7.3 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 40.55% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 40.55% YoY) and the FY2025 annual result came in at $6.8 million, up 44.48% from the prior year.
• Accumulated Depreciation advanced to $7.3 million in Q1 2026 per EWTX's latest filing, from $6.8 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $7.3 million in Q1 2026 and troughed at $785000.0 in Q1 2022.
• A 5-year average of $3.4 million and a median of $3.1 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2026: Accumulated Depreciation soared 145.63% in 2023, then surged 40.55% in 2026.
• Over 5 years, Accumulated Depreciation stood at $1.1 million in 2022, then jumped by 145.63% to $2.6 million in 2023, then soared by 79.09% to $4.7 million in 2024, then soared by 44.48% to $6.8 million in 2025, then climbed by 7.93% to $7.3 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $7.3 million, $6.8 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.